The proportion of the United Kingdom population over 75 years of age will increase from around 7% to nearly 11% in the next 50 years, with a disproportionate rise in those over 85 years. There will be a large increase in the number of elderly patients with cancer. Already over one third of cancers are diagnosed in people over 75, yet we do not know how best to investigate and treat cancers in these patients. Many clinical trials have used arbitrary upper age limits. Even trials in allegedly elderly subjects start at age 65. Very few studies include large numbers of old (over 75) or very old (over 85) people. 1 The role and effectiveness of many cancer treatments is therefore not evidence based in those most affected.Studies of cancer care in elderly patients show fewer diagnostic and staging procedures and less treatment with advancing age. Disease specific survival rates decline with age.
Nutritional assessments were performed in three groups of hospitalized elderly women comparable in age and mobility: a group with Alzheimer's disease (ALZ), a multi-infarct dementia group (MID) and a nondemented group (ND). We have shown that: ALZ patients lose weight and on average weigh 21% less than ND patients and 14% less than MID patients. This weight loss is not accounted for by any obvious deficit in food intake, or by malabsorption. Biochemical indices of nutrition are little different in the three groups. The reason for weight loss in ALZ remains uncertain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.